Meet Dr. Brian Druker
"There is no question that we can defeat cancer. What it requires is knowledge. When we understand what is broken, we can fix it." - Brian Druker, M.D., Director, OHSU Knight Cancer Institute
The OHSU Knight Cancer Institute started the revolution in cancer treatments. Dr. Druker’s groundbreaking advances in precision medicine led to the Knight Cancer Challenge: Phil and Penny Knight, pledged $500 million if OHSU can raise an additional $500 million. The pledge followed a $100 million gift from the Knights in 2008.
The institute is dedicated to building on its scientific strengths to better understand how cancer starts and grows. It will expand upon those discoveries to develop next generation early detection tools and technologies.
The following videos feature some of the pioneering work under way at the OHSU Knight Cancer Institute.
One billion dollars raised in Knight Cancer Challenge
The $1 billion fundraising challenge by Nike co-founder Phil Knight and his wife Penny has been met. OHSU announced June 25 that it reached the fundraising goal that triggers the Knights’ gift pledge, which sets a new philanthropic record. OHSU beat the Knights’ deadline by seven months and garnered support from donors in every state in the nation and five countries. Donors were inspired by plans for the first grand-scale program of its kind dedicated to radically transforming early detection of lethal cancers ― one of the biggest unmet needs in cancer care today.
With $1 billion in new funding, the OHSU Knight Cancer Institute will begin fast-track recruitment of 250 to 300 scientists and physician investigators, including about 25 of the world’s top researchers. These leading scientists will be given the financial support they need to ensure they can focus on research rather than administration of grants. Read more
Acting now to change the future
At the Oregon Business Summit, Brian Druker, M.D., shares his strategy for seeking faster, smarter ways to detect and treat cancer.
Decoding the root causes of cancer
Watch Knight Cancer leaders share their vision for a collaboration with Intel Corporation to deploy next-generation computing technologies to advance the field of precision medicine